|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US4485045A
(en)
|
1981-07-06 |
1984-11-27 |
Research Corporation |
Synthetic phosphatidyl cholines useful in forming liposomes
|
|
US4544545A
(en)
|
1983-06-20 |
1985-10-01 |
Trustees University Of Massachusetts |
Liposomes containing modified cholesterol for organ targeting
|
|
US5444156A
(en)
|
1985-07-12 |
1995-08-22 |
Temple University-Of The Commonwealth System Of Higher Education |
Monoclonal antibodies to human plasma prekallikrein
|
|
US4777127A
(en)
|
1985-09-30 |
1988-10-11 |
Labsystems Oy |
Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
|
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
|
EP0296171A4
(en)
|
1986-03-03 |
1989-11-07 |
Brigham & Womens Hospital |
ASSESSMENT PROCEDURE FOR NEPHROTOXICITY.
|
|
US4704692A
(en)
|
1986-09-02 |
1987-11-03 |
Ladner Robert C |
Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
GB8702816D0
(en)
|
1987-02-07 |
1987-03-11 |
Al Sumidaie A M K |
Obtaining retrovirus-containing fraction
|
|
US5219740A
(en)
|
1987-02-13 |
1993-06-15 |
Fred Hutchinson Cancer Research Center |
Retroviral gene transfer into diploid fibroblasts for gene therapy
|
|
US5422120A
(en)
|
1988-05-30 |
1995-06-06 |
Depotech Corporation |
Heterovesicular liposomes
|
|
AP129A
(en)
|
1988-06-03 |
1991-04-17 |
Smithkline Biologicals S A |
Expression of retrovirus gag protein eukaryotic cells
|
|
US5045452A
(en)
|
1988-09-02 |
1991-09-03 |
Brigham And Women's Hospital |
Method for evaluating nephrotoxicity
|
|
WO1990007936A1
(en)
|
1989-01-23 |
1990-07-26 |
Chiron Corporation |
Recombinant therapies for infection and hyperproliferative disorders
|
|
CA2489769A1
(en)
|
1989-03-21 |
1990-10-04 |
Philip L. Felgner |
Expression of exogenous polynucleotide sequences in a vertebrate
|
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
|
AU648261B2
(en)
|
1989-08-18 |
1994-04-21 |
Novartis Vaccines And Diagnostics, Inc. |
Recombinant retroviruses delivering vector constructs to target cells
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
ZA911974B
(en)
|
1990-03-21 |
1994-08-22 |
Res Dev Foundation |
Heterovesicular liposomes
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
DE69233013T2
(de)
|
1991-08-20 |
2004-03-04 |
The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer |
Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
|
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
|
WO1993010218A1
(en)
|
1991-11-14 |
1993-05-27 |
The United States Government As Represented By The Secretary Of The Department Of Health And Human Services |
Vectors including foreign genes and negative selective markers
|
|
GB9125623D0
(en)
|
1991-12-02 |
1992-01-29 |
Dynal As |
Cell modification
|
|
FR2688514A1
(fr)
|
1992-03-16 |
1993-09-17 |
Centre Nat Rech Scient |
Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
|
|
US5733743A
(en)
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
|
EP0650370A4
(en)
|
1992-06-08 |
1995-11-22 |
Univ California |
METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
|
|
CA2137361A1
(en)
|
1992-06-10 |
1993-12-23 |
W. French Anderson |
Vector particles resistant to inactivation by human serum
|
|
GB2269175A
(en)
|
1992-07-31 |
1994-02-02 |
Imperial College |
Retroviral vectors
|
|
EP1024198A3
(en)
|
1992-12-03 |
2002-05-29 |
Genzyme Corporation |
Pseudo-adenoviral vectors for the gene therapy of haemophiliae
|
|
US5981568A
(en)
|
1993-01-28 |
1999-11-09 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
|
PT695169E
(pt)
|
1993-04-22 |
2003-04-30 |
Skyepharma Inc |
Lipossomas multivesiculares de ciclodextrina encapsulando compostos farmacologicos e metodos para a sua utilizacao
|
|
EP0705344B8
(en)
|
1993-06-24 |
2006-05-10 |
Advec Inc. |
Adenovirus vectors for gene therapy
|
|
DK0814154T3
(da)
|
1993-09-15 |
2009-08-31 |
Novartis Vaccines & Diagnostic |
Rekombinante alfavirusvektorer
|
|
US6015686A
(en)
|
1993-09-15 |
2000-01-18 |
Chiron Viagene, Inc. |
Eukaryotic layered vector initiation systems
|
|
AU687117B2
(en)
|
1993-10-25 |
1998-02-19 |
Canji, Inc. |
Recombinant adenoviral vector and methods of use
|
|
AU686277B2
(en)
|
1993-11-16 |
1998-02-05 |
Pacira Pharmaceuticals, Inc. |
Vesicles with controlled release of actives
|
|
US5795954A
(en)
|
1994-03-04 |
1998-08-18 |
Genentech, Inc. |
Factor VIIa inhibitors from Kunitz domain proteins
|
|
DE69535669T2
(de)
|
1994-05-09 |
2008-12-04 |
Oxford Biomedica (Uk) Ltd. |
Retrovirale vektoren mit verminderter rekombinationsrate
|
|
AU4594996A
(en)
|
1994-11-30 |
1996-06-19 |
Chiron Viagene, Inc. |
Recombinant alphavirus vectors
|
|
US6265150B1
(en)
|
1995-06-07 |
2001-07-24 |
Becton Dickinson & Company |
Phage antibodies
|
|
WO1997042338A1
(en)
|
1996-05-06 |
1997-11-13 |
Chiron Corporation |
Crossless retroviral vectors
|
|
DE19632772A1
(de)
|
1996-08-14 |
1998-02-19 |
Basf Ag |
Neue Benzamidine
|
|
US5840871A
(en)
|
1997-01-29 |
1998-11-24 |
Incyte Pharmaceuticals, Inc. |
Prostate-associated kallikrein
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
WO2000053211A2
(en)
|
1999-03-09 |
2000-09-14 |
University Of Southern California |
Method of promoting myocyte proliferation and myocardial tissue repair
|
|
IL161677A0
(en)
|
2001-11-08 |
2004-09-27 |
Protein Design Labs |
Stable liquid pharmaceutical formulation of igg antibodies
|
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
|
ES2339112T3
(es)
|
2002-08-21 |
2010-05-17 |
BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG |
8-(3-amino-piperidin-1-il)-xantinas,su preparacion y su uso como medicamentos.
|
|
UY28103A1
(es)
|
2002-12-03 |
2004-06-30 |
Boehringer Ingelheim Pharma |
Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos
|
|
US20070253949A1
(en)
|
2004-02-03 |
2007-11-01 |
Stefan Golz |
Diagnostics and Therapeutics for Diseases Associated with Plasma Kallikrein (KLKB1)
|
|
EP1758905B1
(de)
|
2004-02-18 |
2009-04-29 |
Boehringer Ingelheim International GmbH |
8-[3-amino-piperidin-1-yl]-xanthine, deren herstellung und deren verwendung als dpp-iv hemmer
|
|
CA2575791A1
(en)
|
2004-08-03 |
2006-02-16 |
Dyax Corp. |
Hk1-binding proteins
|
|
DE102004044221A1
(de)
|
2004-09-14 |
2006-03-16 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
|
US7235530B2
(en)
|
2004-09-27 |
2007-06-26 |
Dyax Corporation |
Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
|
|
WO2007104541A2
(en)
|
2006-03-16 |
2007-09-20 |
Dyax Corp. |
Compositions and methods using serine protease inhibiting peptides for treating ophthalmic disorders
|
|
KR100846354B1
(ko)
*
|
2007-03-21 |
2008-07-15 |
(주) 프로탄바이오 |
혈청 당단백질부터 분리한 폐암 진단용 마커
|
|
WO2009026539A1
(en)
*
|
2007-08-23 |
2009-02-26 |
Genzyme Corporation |
Treatment with kallikrein inhibitors
|
|
CN101928346B
(zh)
|
2009-07-31 |
2013-01-16 |
华中科技大学同济医学院附属同济医院 |
一种抗人组织激肽释放酶单克隆抗体及其制备
|
|
SMT201800552T1
(it)
|
2010-01-06 |
2018-11-09 |
Dyax Corp |
Proteine che legano la callicreina plasmatica
|
|
KR102320178B1
(ko)
*
|
2011-01-06 |
2021-11-02 |
다케다 파머수티컬 컴패니 리미티드 |
혈장 칼리크레인 결합 단백질
|
|
WO2012142308A1
(en)
|
2011-04-13 |
2012-10-18 |
Activesite Pharmaceuticals, Inc. |
Prodrugs of inhibitors of plasma kallikrein
|
|
MX367097B
(es)
|
2011-05-02 |
2019-08-05 |
Millennium Pharm Inc |
FORMULACION PARA ANTICUERPO ANTI-A4ß7.
|
|
JP6345123B2
(ja)
|
2012-02-16 |
2018-06-20 |
サンタラス， インコーポレイテッド |
抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物
|
|
US9216219B2
(en)
|
2012-06-12 |
2015-12-22 |
Novartis Ag |
Anti-BAFFR antibody formulation
|
|
EP4234583A3
(en)
|
2013-01-20 |
2024-01-24 |
Takeda Pharmaceutical Company Limited |
Evaluation and treatment of bradykinin-mediated disorders
|
|
US10690670B2
(en)
|
2013-01-20 |
2020-06-23 |
Dyax Corp. |
Assays for determining levels of plasma protease C1 inhibitor
|
|
AU2014240045A1
(en)
|
2013-03-15 |
2015-09-10 |
Dyax Corp. |
Anti-plasma kallikrein antibodies
|
|
KR20140119396A
(ko)
|
2013-03-29 |
2014-10-10 |
삼성전자주식회사 |
단백질 약물의 액상 제형
|
|
EA038532B1
(ru)
|
2014-01-21 |
2021-09-10 |
Такеда Фармасьютикал Компани Лимитед |
Способ лечения наследственного ангионевротического отека (hae)
|
|
US10428158B2
(en)
|
2014-03-27 |
2019-10-01 |
Dyax Corp. |
Compositions and methods for treatment of diabetic macular edema
|
|
KR102607829B1
(ko)
|
2015-03-30 |
2023-12-01 |
다케다 파머수티컬 컴패니 리미티드 |
혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 예방하기 위한 이의 용도
|
|
EP3387018A1
(en)
|
2015-12-11 |
2018-10-17 |
Dyax Corp. |
Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
|
|
CN113056304A
(zh)
|
2018-08-30 |
2021-06-29 |
戴埃克斯有限公司 |
用于治疗遗传性血管性水肿发作的血浆激肽释放酶抑制剂及其用途
|
|
AU2020237259A1
(en)
|
2019-03-14 |
2021-10-14 |
Takeda Pharmaceutical Company Limited |
Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
|